Immuron Reports HY26 Results and Strategic Reset

Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler’s diarrhea (Travelan®), the company is moving into high-value clinical targets like C. dif ...